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Abstract
Background: We aimed to describe specific changes in brain perfusion in patients with dementia with Lewy bodies
(DLB) at both the prodromal (also called mild cognitive impairment) and mild dementia stages, relative to patients
with Alzheimer’s disease (AD) and controls.
Methods: Altogether, 96 participants in five groups (prodromal DLB, prodromal AD, DLB with mild dementia, AD
with mild dementia, and healthy elderly controls) took part in an arterial spin labeling MRI study. Three analyses were
performed: a global perfusion value comparison, a voxel-wise analysis of both absolute and relative perfusion, and a
linear discriminant analysis. These were used to assess the global decrease in perfusion, regional changes, and the
sensitivity and specificity of these changes.
Results: Patterns of perfusion in DLB differed from AD and controls in both the prodromal stage and dementia, DLB
having more deficits in frontal, insular, and temporal cortices whereas AD showed reduced perfusion in parietal and
parietotemporal cortices. Decreases but also increases of perfusion in DLB relative to controls were observed in both
absolute and relative measurements. All these regional changes of perfusion classified DLB patients with respect to
either healthy controls or AD with sensitivity from 87 to 100 % and specificity from 90 to 96 % depending on the stage
of the disease.
Conclusions: Our results are consistent with previous studies. We extend the scope of those studies by integrating
prodromal DLB patients and by describing both hypo- and hyperperfusion in DLB. While decreases in perfusion may
relate to functional impairments, increases might suggest a functional compensation of some brain areas.
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Background
Dementia with Lewy bodies (DLB) is clinically charac-
terized by cognitive impairment together with fluctuat-
ing cognition, parkinsonism, and visual hallucinations. It
is the second most common form of neurodegenerative
dementia after Alzheimer’s disease (AD), accounting for
10–20 % of patients with dementia [1].
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A diagnosis of DLB is difficult to establish since at the
early stage there is no clear cognitive pattern. Symptoms
include non-amnestic mild cognitive impairment (MCI)
[2] and at later stages DLB is mixed with other types of
dementia. Establishing a differential diagnosis is all the
more difficult as patients could present symptoms of AD,
making DLB heterogeneous. Furthermore, clinical crite-
ria lack sensitivity [1, 3, 4] and inter-rater reliability [5],
although new neuropsychological tools have recently been
developed [6, 7]. Therefore, in clinical routine, DLB can
be mistaken for AD [3]. Yet, making an early and accurate
diagnosis is mandatory for prognosis and management,
as well as for pharmacological treatment [1], since some
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drugs such as neuroleptics have shown deleterious effects
in DLB [8, 9].
Brain imaging may provide information to refine the
diagnosis of DLB [10]. As functional changes can precede
atrophy [11], functional neuroimaging may be particularly
relevant to the study of the early stage of DLB. Among
the various methods that assess brain functioning, cere-
bral blood flow (CBF) or brain perfusion can be evaluated
using [15O] positron emission tomography (PET), single
photon emission computerized tomography (SPECT), or
arterial spin labeling (ASL) MRI. To our knowledge, brain
perfusion in DLB has not been evaluated using [15O] PET.
Studies using SPECT have shown occipital hypoperfu-
sion [11–16] together with relatively preserved perfusion
in the medial temporal lobe [14–16] in DLB in contrast
to AD. The frontal, parietal, and cingulate cortices have
also been reported to be altered when compared to elderly
controls [15–17]. Similar results have been reported in
ASL MRI studies [18–20] as well as in [18F]-fluoro-d-
glucose PET studies assessing metabolism [21–27]. Taken
together, these results indicate perfusion changes in DLB
in the dementia stage. Therefore, we still have to assess
early differences of perfusion between DLB and AD, at the
prodromal stage (also named MCI).
Using magnetically labeled arterial blood water as an
endogenous tracer, ASL has the advantage over SPECT
and PET of being non-invasive, available in clinical rou-
tine, more reliable [28], and providing absolute values of
CBF (i.e., without any global CBF weighting by the CBF
of a given brain area, such as the cerebellum). ASL may,
therefore, be a suitable tool for assessing perfusion in a
diagnostic perspective.
In this study, we aimed to describe whole-brain ASL
perfusion changes according to both the diagnosis and the
cognitive impairment. We studied DLB and AD patients.
For both diseases, patients were divided into a prodromal
group and a mild dementia stage group, and we com-
pared them with an elderly control group. We planned
to assess differences between DLB and AD as well as
between prodromal and the mild dementia stage in DLB.
We postulated that ASL MRI would be sufficiently sen-
sitive to detect changes in perfusion even in prodromal
DLB. As global CBF (i.e., whole-brain CBF) seems to
be altered in DLB [18], we also assessed regional CBF




Altogether, 132 participants were recruited for this study,
of which 12 patients were excluded due to motion dur-
ing the MRI acquisition (see the section “MRI process-
ing”), resulting in a total of 120 participants, comprising
44 patients with prodromal DLB (pro DLB group), 16
patients with DLB at the mild dementia stage (mild DLB
group), 13 patients with prodromal AD (pro AD group),
26 patients with AD at the mild dementia stage (mild
AD group), and 21 healthy elderly controls (HC group).
Patients sharing both DLB and AD criteria were not
included in the study. Demographic and clinical data are
presented in Table 1. The five groups were examined by
clinicians with expertise in dementia, who performed a
complete anamnesis andmedical examination. Using [29],
akinesia, rigidity, and tremor at rest were rated from 0
to 4 (0 for no symptoms to 4 for serious impairment).
Fluctuations were assessed with the Mayo Clinic Fluctu-
ations scale [30] and the Newcastle-upon-Tyne Clinician
Assessment of Fluctuation scale [31], and patients with a
score greater than or equal to 2 were considered as having
fluctuations. Cognitive functions were evaluated using the
following tests:
• Mini-Mental State Examination (MMSE) for general
cognitive functions
• The French version of the Free and Cued Selective
Reminding Test, the Delayed Matching-to-Sample
test (48 items), and the digit-span test for memory
functions
• The Dénomination Orale (oral naming test, 80 items)
for language
• The Frontal Assessment Battery, the Trail Making
Test A and B, the Digit Symbol Substitution Test, and
formal and semantic lexical evocation for executive
functions
• The praxis set of Mahieux and the Rey-Osterrieth
complex figure test for praxis
• The number localization and cube analysis of the
Visual Object and Space Perception battery for
visuo-perceptive functions
All patients underwent cerebrospinal fluid analysis,
includingmeasurement of tau, phospho-tau, and amyloid-
beta (1–42) (Innogenetics’s Innotest, ELISA). Assess-
ment of medial temporal lobe atrophy and parietal lobe
atrophy on brain MRI were performed using the stan-
dardized Scheltens scale [32] and the Koedam scale [33]
(5 categories, from 0 to 4 with 0 corresponding to no
atrophy), respectively. Vascular damage in white matter
and basal ganglia was assessed separately according to
the Wahlund scale [34]. An etiologic diagnosis of the
neurocognitive disorder for each patient was made using
Dubois’s criteria for pro AD and mild AD [35], and McK-
eith’s criteria (probable DLB, i.e., at least two core symp-
toms) for mild DLB [1]. Pro DLB patients were defined
as patients with MCI (Petersen criteria) [36], preservation
of independence (assessed by the Instrumental Activi-
ties of Daily Living) and by McKeith’s criteria (meeting
probable DLB criteria except presence of dementia) [1].
The numbers of patients treated with dopaminergic drugs
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Table 1 Demographic and clinical data of participants
Characteristic Pro DLB Mild DLB Pro AD Mild AD HC
Participants 46 16 13 25 21
Female 26 8 4a 17 12
Age, years (SD) 69.4 (8.8) 74.7 (10.2)∗ 74.5 (9.9)∗ 73.6 (9.1)∗ 64.8 (8.6)
MMSE score (SD) (maximum 30) 27.5 (1.4) 20.7 (3.4) 27.1 (1.5) 19.5 (3.4) 28.9 (1.0)
Participants with visual hallucinations 19 9 0 3 0
Participants with parkinsonism 34 11 1 7 0
Participants with cognitive fluctuations 28 9 0 5 0
Medial temporal lobe atrophy (L, R)
Participants with a score of 0 18, 16 6, 4 3, 3 7, 5 13, 9
Participants with a score of 1 11, 12 1, 4 5, 6 5, 9 7, 10
Participants with a score of 2 12, 15 4, 4 4, 4 7, 5 1, 2
Participants with a score of 3 5, 2 3, 2 1, 0 5, 3 0, 0
Participants with a score of 4 0, 1 2, 2 0, 0 1, 3 0, 0
Parietal lobe atrophy (L, R)
Participants with a score of 0 14, 14 9, 8 4, 2 5, 6 7, 8
Participants with a score of 1 16, 17 4, 5 7, 8 8, 6 9, 8
Participants with a score of 2 12, 11 3, 3 2, 3 9, 9 4, 5
Participants with a score of 3 0, 4 4, 0 0, 0 3, 4 0, 0
Participants with a score of 4 0, 0 0, 0 0, 0 0, 0 0, 0
Vascular damage in white matter
Participants with a score of 0 25 4 7 9 7
Participants with a score of 1 15 7 4 7 12
Participants with a score of 2 6 4 1 7 2
Participants with a score of 3 0 1 1 2 0
Vascular damage in basal ganglia
Participants with a score of 0 33 13 10 17 21
Participants with a score of 1 11 1 2 5 0
Participants with a score of 2 2 1 1 0 0
Participants with a score of 3 0 1 0 3 0
Participants with AchI medication 14 11 2 17 0
Participants with dopaminergic medication 13 6 0 0 0
Medial temporal lobe atrophy, parietal lobe atrophy, and vascular damage were assessed according to the Scheltens, Koedam, and Wahlund scales, respectively. Pro AD were
more male than mild AD. Mild DLB, pro AD, and mild AD were older than HC
AchI acetylcholinesterase inhibitor, AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy (elderly) controls, L left hemisphere,MMSE Mini-Mental State
Examination, R right hemisphere, SD standard deviation
*p < 0.05
ap < 0.01
or cholinesterase inhibitors are listed in Table 1. The con-
trol group consisted of elderly healthy and cognitively
intact (no MCI) subjects who were recruited via adver-
tisements in local community newsletters in Strasbourg,
and via the listing of controls of the local clinical investi-
gation center (Centre d’Investigation Clinique) in charge
of any type of medical research of the University Hospital
of Strasbourg. Exclusion criteria for participation in the
study included contraindications for MRI, history of alco-
hol or substance misuse, evidence suggesting alternative
neurological or psychiatric explanations for their symp-
toms or cognitive impairment, focal brain lesions on brain
imaging, and the presence of other severe or unstable
medical illness. All patients had a formal assessment of
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their diagnosis by three independent expert clinicians (FB,
BC, and NP) and controls underwent similar clinical and
cognitive assessments to exclude any who may have had
occult MCI or dementia. Patients with concomitant AD
and DLB, i.e., meeting both McKeith’s (for probable DLB)
and Dubois’s criteria were also excluded.
The study was approved by the local Ethics Committee
(Comité de Protections des Personnes Est IV, Strasbourg,
France). Controls and patients gave written informed
consent.
Data acquisition
The pulsed ASL sequence was performed on a Siemens
Verio 3T scanner equipped with a 32-channel head coil
(Siemens, Erlangen, Germany). In total, 121 whole-brain
T2∗-weighted (gradient echo) echo planar images were
acquired using the QUIPPS II sequence provided by the
manufacturer. The parameters were:
• Repetition time (TR): 3 s
• Flip angle: 90°
• Echo time (TE): 21 ms
• Inversion time 1 (TI1): 600 ms
• Inversion time 2 (TI2): 1325.1 ms
• Field of view (FOV): 152 × 256 × 112mm
• Imaging matrix: 38 × 64 × 28
• 4 mm3 isotropic voxels, acceleration factor
(generalized auto-calibrating partially parallel
acquisitions [GRAPPA]): 2
The tagged volume was 10 cm thick, positioned at the
neck, and its distal part was 23 mm below the first slice to
avoid saturation. Bipolar gradients were used to eliminate
the signals from fast moving spins (>10 cm·s−1). The first
volume recorded corresponded to M0, and non-tagged
images were acquired in alternation with tagged images.
A 3D MPRAGE T1-weighted image was also acquired
at the same session. The parameters were: imaging matrix
192 × 192 × 176 and 1 mm3 isotropic voxels.
MRI processing
Images were processed using SPM8 (Welcome Depart-
ment of Cognitive Neurology, London, UK) and in-house-
developed software. All data were processed for each
participant separately.
Functional images were first corrected for motion
and magnetic field B0 inhomogeneities. According to
the motion parameters provided by SPM, patients with
translations and rotations higher than 2 mm and 2°,
respectively, were removed from the analysis. As the
TE is high enough to make the ASL sequence sensitive
to blood oxygen level-dependent fluctuations, the sig-
nals were high-pass filtered at 0.1125 Hz according to
the method of Chuang et al. [37]. One CBF map per
subject was then calculated according to the TE-corrected
method published by Foucher et al. [38]. The M0 map
was coregistered to the T1 image and the transforma-
tion parameters were used to coregister the CBF map
in the same way. The T1 image was segmented using
the New Segment toolbox, leading to five high defini-
tion maps (gray and white matter, cerebrospinal fluid,
meninges, and bones). The first three served as a brain
mask to exclude non-cerebral voxels from the CBF map.
Gray and white matter probability maps also served to cal-
culate spatial normalization parameters to the Montreal
National Institute (MNI) space according to the DAR-
TEL approach. T1 and CBF maps were then spatially
normalized according to the normalization parameters.
During this procedure, CBF maps were smoothed (full
width at half maximum of 8 × 8 × 8 mm) but not
modulated.
Statistical analyses
Analyses were performed in Matlab (R2012b, Mathworks,
Natick, MA). The gender and age distribution between
groups were assessed by chi-squared tests and a one-
way ANOVA, respectively. A global decrease in perfu-
sion in patients relative to healthy controls was evaluated
by two-sample T-tests on values of whole-brain mean
perfusion.
Voxel-wise statistical analyses of perfusion were per-
formed using ANOVA, with age [39, 40] and gender
[40] as regressors of non-interest. These analyses were
both conducted in absolute and relative measurements,
the latter being corrected for the global mean value.
The relative measurement corrects for inter-individual
differences in global perfusion and explains local differ-
ences in perfusion. The statistical analyses combined a
puncorrected < 0.001 threshold at the voxel level with
a cluster size threshold of 40 voxels (i.e., 320 mm3).
Following a multiple comparison correction (familywise
error or FWE) of pFWE < 0.05 at the cluster level,
significant clusters in the tables are identified by a
superscript.
The clusters resulting from the voxel-wise analyses were
subsequently considered as regions of interest (ROIs) in a
two-class k-means classification and a linear discriminant
analysis. The k-means analysis classified the patients and
HC and provided the values of sensitivity and specificity
for the patient group (or for DLB when the comparison
concerned DLB versus AD). The discriminant analysis
modeled the difference in perfusion between groups. As
we aimed to model it with the simplest equation, we chose
the shortest combination of ROIs that maximized the val-
ues of sensitivity and specificity (to assess for sensitivity
and specificity, a leave-one-out cross-validation was used
and the estimated classification was compared to the true
diagnosis).
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Results
Demographic data are presented in Table 1. Age differed
between groups (F[ 4, 116] ) = 4.4; p < 0.01): mild DLB,
pro AD, and mild AD being older than HC (p < 0.05).
The proportion of male patients was higher in the pro AD
group than in the mild AD group (p < 0.01).
Perfusion in prodromal patients
The difference in global perfusion relative to HC was sig-
nificant in the pro AD group (p < 0.05) but not in the pro
DLB group.
The results for focal relative perfusion in prodromal
patients are presented in Table 2 and Fig 1. Hypoperfusion
in pro DLB compared to HC occurred in the right frontal,
parietal, and temporal cortex together with the anterior
insula. Only the left superior frontal gyrus showed an
increase in relative perfusion in pro DLB. Absolute hypop-
erfusion gave similar results with a loss of perfusion in the
right temporal and anterior insula, whereas the left supe-
rior frontal gyrus was hyperperfused (Additional file 1:
Table S1 and Figure S1. Please refer to these supple-
mentary data for all results of absolute perfusion). Pro
AD showed hypoperfusion compared to HC in the right
inferior frontal gyrus and bilateral angular gyrus, and
hyperperfusion was seen in the left supramarginal gyrus
(absolute assessment showed a similar pattern of hypop-
erfusion, but without any increase in perfusion relative to
HC). Comparison between pro DLB and pro AD revealed
a lower relative perfusion in DLB in the fusiform gyrus (as
with absolute measurements). Pro AD did not have any
hypoperfused brain areas relative to pro DLB (but abso-
lute measurements showed a decrease in the left angular
gyrus).
Perfusion in patients with dementia
The difference in global perfusion relative to HC showed
a trend towards statistical significance in mild AD (p =
0.059), but not in mild DLB.
Mild DLB patients showed a variety of hypoperfused
brain areas compared to HC (Table 3 and Fig 2), includ-
ing the frontal and temporal cortex, bilateral anterior
insula, and caudate nucleus (as in absolute measurement;
see Additional file 1: Table S2 and Figure S2). Hyper-
perfusion in mild DLB patients was observed mainly
in the left precuneus. In mild AD, compared to HC,
perfusion was reduced in parietal and temporal areas
(assessment of absolute perfusion provided a similar pat-
tern), whereas hyperperfusion was restricted to the left
putamen (no increases in mild AD were revealed with
absolute perfusion).When patient groups were compared,
mild DLB showed a lower perfusion than mild AD in
the frontal and temporal cortices together with the left
supramarginal gyrus, anterior insula, and caudate nucleus
(a difference in absolute perfusion only concerned the
anterior insula and the supramarginal and superior tem-
poral gyri). In contrast, mild AD had a reduced rCBF in
the bilateral precuneus, left supramarginal, and medial
superior frontal gyri (only the bilateral precuneus and
the left supramarginal gyrus in assessment of absolute
perfusion).
Table 2 Significant changes in relative perfusion in prodromal patients
Contrast Region Laterality Extent Coordinates (x, y, z) Sensitivity Specificity
Pro DLB < HC Middle temporal R 960 38 –58 6 65 76
Anterior insula
R 840 36 34 0 74 90
Inferior frontal
Superior parietal R 648 16 –62 50 80 62
Superior orbital R 336 18 66 –14 54 95
Pro DLB > HC Superior frontal L 432 –16 32 38 57 90
Pro AD < HC Angular R 1280 42 –54 28 100 95
Angular L 448 –38 60 26 92 76
Inferior frontal R 400 34 38 0 76 92
Pro AD > HC Supramarginal L 432 –62 –24 26 69 90
Pro DLB < pro AD Fusiform R 984 34 –30 –18 72 69
Pro AD < pro DLB – – – – – – – –
Extent is expressed in mm3. Coordinates are in the Montreal National Institute space. Sensitivity and specificity are percentages, relative to DLB identification except for
comparison between pro AD and HC
AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy (elderly) controls, L left hemisphere, R right hemisphere
Roquet et al. Alzheimer’s Research & Therapy  (2016) 8:29 Page 6 of 13
Fig. 1 Statistical maps of relative perfusion in prodromal patients and healthy controls. Numbers are z-coordinates in the MNI space. Left column:
Pro DLB minus HC.Middle column: Pro AD minus HC. Right column: Pro DLB minus pro AD. Positive (red) and negative (blue) T -values are,
respectively, hyper- and hypoperfusion resulting from a voxel-wise ANOVA (puncorrected < 0.001, cluster size threshold of 40 voxels). The anatomical
image used as a template is an average T1 from the encompassed groups. AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy
(elderly) controls,MNIMontreal National Institute
Perfusion according to the level of cognitive impairment
Patients at different stages of the same disease were
also compared, i.e., prodromal groups were compared
to mild dementia groups. Mild DLB had lower perfu-
sion than pro DLB in the left anterior insula, the inferior
frontal gyrus, the right anterior and middle cingulum, the
bilateral middle temporal gyrus, and the caudate nuclei
(Table 4 and Fig. 3) (absolute perfusion revealed a simi-
lar pattern of decreasing perfusion; see Additional file 1:
Table S3 and Figure S3). Mild AD had reduced perfu-
sion compared to pro AD in the right precuneus and
the left inferior parietal lobule (only the inferior pari-
etal lobule was significant in measurement of absolute
perfusion).
Discriminant analysis
The linear discriminant analysis revealed the optimal
weighting for the combination of ROIs that best segre-
gated the two populations. We performed this analysis
for all possible combinations of ROIs resulting from the
voxel-wise comparisons. Since only cluster was signif-
icant between pro DLB and pro AD, no discriminant
analysis was performed on this contrast. We obtained
the most accurate classification compared to the medi-
cal diagnosis with the linear discriminant analysis formula
shown in Table 5 (for discriminant analysis with abso-
lute measurements of perfusion, see Additional file 1:
Table S4). Values of sensitivity and specificity were good
to perfect (Table 5). Nevertheless, they were higher when
discriminating mild DLB than when discriminating pro
DLB. No discriminant analysis was performed on the con-
trast between pro AD and HC since there was only one
cluster.
Discussion
Our aim was to describe brain perfusion disorders in
the early stages of DLB using the pulsed ASL tech-
nique. We performed whole-brain voxel-wise analyses
to compare two stages of DLB and AD, i.e., prodro-
mal (or MCI) and dementia, as well as a fifth group
of elderly controls. To evaluate whether perfusion MRI
would help with diagnosis, we used classification tools (k-
means and discriminant analysis) to assess the sensitivity
and specificity of each significant cluster resulting from
the voxel-wise analysis, and of specific combinations of
clusters.
Roquet et al. Alzheimer’s Research & Therapy  (2016) 8:29 Page 7 of 13
Table 3 Significant changes in relative perfusion in patients with mild dementia
Contrast Region Laterality Extent Coordinates (x, y, z) Sensitivity Specificity






L –10 14 4
Middle temporal L 2456 –54 –20 –14 81 86
Middle temporal R 2064 42 –52 8 75 76
Anterior insula
R 1560 36 36 0 81 100
Inferior frontal
Anterior insula L 1072 –30 22 6 75 90
Inferior frontal L 576 –34 12 24 75 67
Mild DLB > HC Precuneus L 952 –6 –60 58 50 100
Mild AD < HC Inferior parietal L 1640 –46 –42 48 72 86
Superior parietal
R 1440 16 –62 50 84 67
Precuneus
Superior temporal R 584 44 –48 18 84 76
Precentral sulcus L 472 –34 4 44 96 52
Middle temporal R 360 62 –42 14 72 81
Superior temporal L 352 –42 –42 0 80 76
Mild AD > HC Putamen L 352 –30 –4 –12 60 86
Anterior insula
L 2168 –28 26 2 88 84
Inferior frontal
Superior temporal R 1416 –56 –18 4 94 88
Caudate nucleus L 1016 –14 16 –6 81 68
Mild DLB < mild AD Inferior frontal R 752 36 38 –2 88 76
Supramarginal L 752 –44 –28 34 88 72
SMA R 704 12 –6 54 69 92
Inferior frontal L 496 –38 12 22 63 80
Middle temporal L 480 –64 –20 –10 69 92
Mild AD < mild DLB Precuneus∗ LR 2896 2 –60 52 69 92
Medial superior frontal L 704 –2 60 32 69 92
Medial superior frontal L 584 –2 46 44 69 92
Supramarginal L 496 –56 –30 24 69 92
Extent is expressed in mm3. Coordinates are in the Montreal National Institute space. Sensitivity and specificity are percentages, relative to DLB identification except for
comparison between mild AD and HC
AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy (elderly) controls, L left hemisphere, R right hemisphere, SMA supplementary motor area
*pFWE < 0.05
Changes in DLB
Care is needed when interpreting differences in perfusion,
particularly when two diseases or two stages of the same
disease are being compared. Both hypo- and hyperper-
fusion were indeed observed in DLB relative to controls,
suggesting distinct phenomena. Hypoperfusion occurred
mainly in the middle temporal gyrus, and the right frontal
and anterior insula in pro DLB; it then extended to the
contralateral hemisphere and to the caudate nuclei when
the disease worsened. This expansion of hypoperfused
areas when the cognitive impairment increases was con-
firmed by contrasting pro DLB and mild DLB since it
provided a similar pattern (plus the middle and ante-
rior cingulum). Frontal and temporal hypoperfusion is
consistent with previous reports [18, 20]. Hypoperfu-
sion in prefrontal areas may be associated with impair-
ment in DLB of executive functions [41] and attention
[42], whereas the deficit in middle temporal areas would
instead relate to memory [43]. A previous study on hallu-
cination in AD [44] reported that the right anterior insula
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Fig. 2 Statistical maps of relative perfusion in patients with mild dementia and healthy controls. Numbers are z-coordinates in the MNI space. Left
column: Mild DLB minus HC.Middle column: Mild AD minus HC. Right column: Mild DLB minus mild AD. Positive (red) and negative (blue) T -values are,
respectively, hyper- and hypoperfusion resulting from a voxel-wise ANOVA (puncorrected < 0.001, cluster size threshold of 40 voxels). The anatomical
image used as a template is an average T1 from the encompassed groups. AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy
(elderly) controls,MNIMontreal National Institute
may be involved in the process of hallucination, suggest-
ing that the early impairment of the anterior insula we
described may be involved in the occurrence of halluci-
nations. The decrease in CBF in the caudate nuclei may
instead be related to parkinsonism. According to previ-
ous studies, occipital hypoperfusion seems to be a core
feature of DLB and may be related to visual hallucina-
tions [14, 45]. Moreover, patients with DLB commonly
present visual perceptual and visuospatial dysfunctions
[46]. In our study, pro DLB and mild DLB did not show
occipital hypoperfusion. However, a very strong effect of
age was observed in the occipital cortex, which may mask
the effect of the pathology and explain some discrepan-
cies with previous studies, as most of them did not correct
for age. The early stages of the disease and the number of
patients who complain of visual hallucinations and visual
impairment may also explain this difference [14]. Further
correlates between perfusion and cognitive performances
would provide information about variants in the first stage
of DLB. In addition to the hypoperfusion pattern, the
frontal cortex in pro DLB and the precuneus in mild DLB
showed an increase in CBF compared to HC (contrasting
pro DLB with mild DLB confirmed these results). Such
observations are only partly due to the relative assessment
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Table 4 Significant changes of relative perfusion according to the level of cognitive impairment
Contrast Region Laterality Extent Coordinates (x, y, z)
Mild DLB < pro DLB Caudate nucleus∗ L 4968 –12 6 12
Inferior frontal L 2064 –32 14 24
Middle temporal L 1320 –58 –10 –18
Anterior insula L 1144 –28 24 4
Caudate nucleus R 936 10 10 4
Middle cingulum R 880 10 4 42
Anterior cingulum R 704 16 34 20
Middle temporal R 456 60 –12 –16
Middle temporal L 384 –56 –56 8
Pro DLB < mild DLB Precuneus L 744 –4 –60 58
Mild AD < pro AD Inferior parietal L 1544 –60 –46 42
Precuneus R 344 14 –60 28
Pro AD < mild AD Cuneus L 496 16 –102 12
Inferior frontal R 432 34 38 0
Extent is expressed in mm3. Coordinates are in the Montreal National Institute space. Sensitivity and specificity are percentages, relative to DLB identification except for
comparison between AD and HC
AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy (elderly) controls, L left hemisphere, R right hemisphere
*pFWE < 0.05
of perfusion (by correcting for the whole-brain mean
value), as absolute perfusion also revealed these hyperper-
fused regions. Whereas hypoperfusion relative to controls
may reflect a decrease in neuronal activity in patients,
hyperperfusion may reveal a compensatory process by
which patients make up for the initial neuronal disorders
[47–49]. Therefore, assessing perfusion seems to indicate
a disorganization in DLB of some parts of the cortex, with
both under- and over-activated areas.
Changes in AD
Perfusion in AD was mainly reduced in the parietal and
parietotemporal cortex, where the deficit started as early
as the prodromal stage. Such impairments are in accor-
dance with previous studies using ASL [50, 51], SPECT
[13, 52], or PET [24]. Our data also showed that perfu-
sion in these areas decreased with the cognitive decline
(i.e., from theMCI stage to dementia).While our transver-
sal study was not designed to compare the prodromal
patients who convert to dementia to those who do not,
the hypoperfusion we observed in the parietal and pari-
etotemporal cortex and the fusiform gyrus has been
reported by other groups as a predictor of conversion
to dementia [53, 54]. Exploring perfusion according to
the cognitive profile of patients with AD suggested that
such hypoperfusion relates to the impairment of execu-
tive functions [55] and memory [56, 57]. We found that
pro AD had lower perfusion than mild AD in the inferior
frontal gyrus and the cuneus, which, according to our
results and previous reports [15], is more typical of DLB.
This counterintuitive result could reflect the lack of sensi-
tivity of the DLB criteria [1, 3, 4], reinforcing the need for
new biomarkers of DLB. Another explanation would be a
compensatory phenomenon in mild DLB with hyperacti-
vation in the frontal and occipital cortices.
Changes between DLB and AD
Hypoperfusion in DLB relative to AD mainly occurred
in the frontal cortex, the anterior insula, and the caudate
nuclei, and in parts of the temporal cortex and supplemen-
tary motor area. Hypoperfusion in AD relative to DLBwas
in the medial frontal cortex and the parietal lobe. Hypop-
erfusion was unsurprisingly more extensive in dementia
than in MCI, a finding that could be related to the stage
of the disease but also to a lack of statistical power
given the lower number of patients in the pro AD group.
These patterns mainly agreed with the comparisons to
HC. They are also in accordance with previous reports
[18, 20] but differ in terms of occipital hypoperfusion in
mild DLB (although Fong et al. [20] did not show occip-
ital hypoperfusion either). The differences in perfusion
between DLB and AD are consistent with the cogni-
tive profiles of the diseases, the former being predom-
inantly a frontal (and occipital) related disease and the
latter being a posterior and medial temporal lobe related
disease.
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Fig. 3 Statistical maps of relative perfusion according to the level of cognitive impairment. Numbers are z-coordinates in the MNI space. Left column:
Pro DLB minus mild DLB. Right column: Pro AD minus mild AD. Positive (red) T-values are hypoperfusion in the mild groups resulting from a
voxel-wise ANOVA (puncorrected < 0.001, cluster size threshold of 40 voxels). The anatomical image used as a template is an average T1 from the
encompassed groups. AD Alzheimer’s disease, DLB dementia with Lewy bodies,MNIMontreal National Institute
Table 5 Linear discriminant analysis to classify subjects according to their relative pattern of perfusion
Contrast Regions of interest Coefficient Constant Sensitivity Specificity
Pro DLB vs HC Middle temporal (R) 5.5 –24.1 87 90
Anterior insula/inferior frontal (R) 9.2
Superior parietal (R) 8.1
Superior orbitofrontal (R) 5.1
Superior frontal (L) –5.9
Mild DLB vs HC Caudate nucleus (LR) 19.8 –38.5 94 95
Middle temporal (R) 13.3
Anterior insula/inferior frontal (R) 4.8
Anterior insula (L) 8.4
Mild DLB vs mild AD Superior temporal (R) 9.2 –12.5 100 96
Caudate nucleus (L) 5.1
Inferior frontal (L) 9.4
Precuneus (LR) –2.8
Supramarginal (L) –12.8
Coefficients are mean coefficients (leave-one-out cross-validation) corrected for age and gender. As an example, to distinguish mild DLB from HC: Classification = constant +
mean perfusion in bilateral caudate nucleus × 19.8 + mean perfusion in right middle temporal gyrus × 13.3 + mean perfusion in right anterior insula × 4.8 + mean perfusion
in left anterior insula × 8.4
AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy (elderly) controls, L left hemisphere, R right hemisphere
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Sensitivity and specificity
Discriminant analyses of the perfusion differences
between DLB and HC and between DLB and AD provided
good values of sensitivity and specificity, even with a
small set of ROIs (sensitivity from 87 to 100 %; specificity
from 90 to 96 %). These values were higher than those
in previously published results obtained using SPECT
[11, 12, 14, 15, 58] and PET [21, 24]. They were processed
to give higher values than each ROI taken individually.
Although mild DLB was more accurately classified than
pro DLB, the good sensitivity and specificity suggest that
DLB and AD could be differentiated at an early stage of
the disease, such as the prodromal stage. It is noteworthy
that the voxel-wise analysis and the discriminant analysis
were performed on the same subjects since the sample
size was too low to divide the groups into a learning and a
testing data set. Therefore, the circular analysis we used
can provide high values of sensitivity and specificity,
which has to be considered as the upper limit of what can
be achieved by a pulsed ASL study in discriminating DLB
from HC and AD.
Relative and absolute perfusion
Whole-brain CBF has been reported to be globally
reduced in DLB [18]. Our results were not in line with this
finding since AD but not DLB showed a global decrease of
perfusion. This global reduction might mask some hyper-
activation relative to whole-brain functioning and make
the hypoperfusion pattern look more consistent that it
actually is. By taking into account the mean perfusion,
i.e., assessing relative perfusion as in SPECT, we described
some local brain hypo- and hyperperfusion in DLB that
was only partly observed in absolute values.
Limitations
Some of the changes in perfusion observed in this study
may partly be due to atrophy, even though we limited
this bias by using the DARTEL normalization procedure
(a common template across healthy subjects and patients
was created) without modulation of the perfusion images
(i.e., areas that were expanded or shrank to match the
common template were not modified in intensity of per-
fusion). In this study, we assessed perfusion in DLB with
a pulsed ASL sequence as did Taylor et al. [19], whereas
other groups used pseudocontinuous [18] or continuous
ASL [20]. Although the pseudocontinuous labeling tech-
nique has greater sensitivity than pulsed and continuous
ASL, their intra- and mutli-center reproducibility is rea-
sonable for the three ASL techniques [59]. Therefore,
some differences between DLB, AD, and HC may still
be hidden when using the pulsed ASL sequence, but the
significant differences we found may not depend on the
sequence. Another limitation of the study is the impact
on statistical power due to differences in the number
of participants between groups. As a consequence, some
brain dysfunctions may have been underestimated. Other
group differences could nevertheless be limited by the
covariates: although the proportion of males was higher in
the pro AD group than in the other groups, we accounted
for gender in the statistical analyses, as we did for age.
Lastly, although we used a leave-one-out cross-validation
to classify the patients according to their perfusion pat-
tern, a validation using other data sets will need to be
performed. Nevertheless, this is one more step towards a
multi-sequence and multi-MRI validation.
Conclusions
This whole-brain voxel-wise study demonstrates that ASL
can reveal specific changes in brain perfusion in DLB,
even in its early stage such as in MCI. By combining per-
fusion values from a few ROIs, DLB can be differentiated
from both AD and controls.
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